An Op-Ed piece by I-MAK’s Director of IP, Tahir Amin, on the Novartis case. “This could have consequences on how pharmaceutical companies now seek to draft their patent applications in India realising they cannot set one patent up in preparation for the next one – call it incremental patenting – a practice that is all too accepted in developed country patent systems and part of the product life cycle management strategy.”
Learn more about how you can help build a more equitable system for all Notice: JavaScript is required for this content.